Asset Details
Do you wish to reserve the book?
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Do you wish to request the book?
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
2019
Overview
Neuromyelitis optica spectrum disorder is a relapsing inflammatory disorder of the central nervous system. Two thirds of patients have antibodies against aquaporin-4, and CNS damage is complement dependent. The inhibitor of terminal complement C5 cleavage, eculizumab, reduced relapses of NMOSD.
Publisher
Massachusetts Medical Society
Subject
/ Antibodies, Monoclonal, Humanized - adverse effects
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Complement C5 - antagonists & inhibitors
/ Complement Inactivating Agents - adverse effects
/ Complement Inactivating Agents - therapeutic use
/ Design
/ Empyema
/ Female
/ Headache
/ Headache - chemically induced
/ Humans
/ Immunosuppressive Agents - adverse effects
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Neuromyelitis Optica - drug therapy
/ Neuromyelitis Optica - immunology
